Marinus Pharmaceuticals (MRNS) is a clinical stage biopharmaceutical company focused on developing and commercializing innovative therapeutics to treat epilepsy and neuropsychiatric disorders. Their clinical stage product candidate ganaxolone, is a positive allosteric modulator of GABA and is being developed in three different dose forms: intravenous (IV), capsule, and liquid. These multiple dose forms are intended to maximize the therapeutic range of ganaxolone for adult and pediatric patient populations, in both acute and chronic care, as well as inpatient and self-administered settings. Ganaxolone seems to exhibit anti-seizure and anti-anxiety actions via its effects on synaptic and extrasynaptic GABAA receptors. It offers a new mechanism of action (MOA), an extensive safety database, and convenient dosing to potentially improve the lives of patients suffering from drug-resistant seizures and neuropsychiatric disorders.